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Ependymal tumors are rare central nervous system 
tumors.1 According to the Central Brain Tumor Registry 
of the United States, the annual incidence of ependymal 
tumors is estimated at 0.43 patients per 100 000 popula-
tion.2 These tumors account for 1.8% of all primary CNS 
tumors and for 6.8% of all gliomas.2 In children (0–19 y of 
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Abstract
Ependymal tumors are rare CNS tumors and may occur at any age, but their proportion among primary brain 
tumors is highest in children and young adults. Thus, the level of evidence of diagnostic and therapeutic interven-
tions is higher in the pediatric compared with the adult patient population.
The diagnosis and disease staging is performed by craniospinal MRI. Tumor classification is achieved by histo-
logical and molecular diagnostic assessment of tissue specimens according to the World Health Organization 
(WHO) classification 2016. Surgery is the crucial initial treatment in both children and adults. In pediatric patients 
with intracranial ependymomas of WHO grades II or III, surgery is followed by local radiotherapy regardless of 
residual tumor volume. In adults, radiotherapy is employed in patients with anaplastic ependymoma WHO grade 
III, and in case of incomplete resection of WHO grade II ependymoma. Chemotherapy alone is reserved for young 
children <12 months and for adults with recurrent disease when further surgery and irradiation are no longer feas-
ible. A gross total resection is the mainstay of treatment in spinal ependymomas, and radiotherapy is reserved for 
incompletely resected tumors. Nine subgroups of ependymal tumors across different anatomical compartments 
(supratentorial, posterior fossa, spinal) and patient ages have been identified with distinct genetic and epigen-
etic alterations, and with distinct outcomes. These findings may lead to more precise diagnostic and prognostic 
assessments, molecular subgroup-adapted therapies, and eventually new recommendations pending validation 
in prospective studies.
Key words  
adults | children | ependymoma | molecular pathology | treatments
Downloaded from https://academic.oup.com/neuro-oncology/advance-article-abstract/doi/10.1093/neuonc/nox166/4673200
by University of Torino user
on 11 January 2018
 2 Rudà et al. EANO guidelines on ependymomas
age), ependymal tumors are proportionally more common 
and account for 5.2% of all primary CNS tumors.2 Overall, 
these tumors affect males more frequently than females 
(1.3:1).
Ependymal tumors are of neuroectodermal origin and 
subdivided according to the World Health Organization 
(WHO) classification of CNS tumors into distinct entities 
and histological variants.3 The WHO classification also 
comprises a histological grading into 3 distinct grades of 
malignancy: WHO grades I, II, and III.
In addition to age and tumor grade, the prognosis is 
associated with tumor location (supratentorial, infraten-
torial, and spinal) and site-specific molecular genetics.4–7 
Population-based epidemiological data reported a 5-year 
overall survival (OS) rate of 83.4% and a 10-year OS rate of 
79.1% in patients with ependymal tumors.2
A recent molecular classification has distinguished 9 
subgroups of ependymal tumors that appear to reflect 
more precisely than histology alone the biological, clinical, 
and histopathological heterogeneity across the major ana-
tomical compartments, age groups, and tumor grades.6 
Each of the 9 molecular subgroups is characterized by 
distinct DNA methylation profiles and associated genetic 
alterations.
Prospective studies on management of ependymoma 
patients have been performed in the pediatric population 
only, while smaller retrospective series are available for 
adult patients.8 In this guideline, we have separated the 
review of evidence concerning diagnosis and treatment 
recommendations for children and adults, recognizing 
that this is somewhat artefactual and may be replaced by 
molecular profiling-based stratification for treatment in the 
future.
Methods
The European Association of Neuro-Oncology (EANO) 
ependymoma task force assessed the available English 
literature up to December 31, 2016, sorted the scientific 
evidence into classes I–IV, and rated recommendations at 
levels A–C according to the European Federation of the 
Neurological Societies Guidelines.9 When sufficient evi-
dence for recommendations was not available, the task 
force offered advice as a Good Practice Point. Specific rec-
ommendations for the therapeutic management of epend-
ymomas in adults and children are reported in Tables 1–6.
Importance of the study
This article reports the evidence-based guidelines on 
management of ependymal tumors in children and 
adults developed by a multidisciplinary task force of 
the European Association of Neuro-Oncology, com-
posed of medical experts from different European coun-
tries representing the involved disciplines (neurology, 
neurosurgery, neuropathology, radiation oncology, 
and pediatric oncology). These guidelines should aid all 
professionals involved in the management of patients 
with ependymal tumors in the daily clinical practice and 
could serve as a source of knowledge for institutions and 
insurance companies involved in cancer care in Europe.
Table 1 Key recommendations for the treatment of newly diagnosed intracranial WHO grades II and III ependymomas in adults
Class of 
Evidence
Level of Recommendation
Resection is recommended to obtain a histological diagnosis and should be a gross total 
resection whenever feasible. As the morbidity can be significant, detailed informed pre-
operative counseling by a surgeon experienced in performing such surgery is important.
II B
Postoperative MRI should be performed to evaluate the extent of resection. n.a. Good Practice Point
A second-look surgery should be considered when the result of the first resection has 
not been satisfactory.
III C
Because a risk of CSF dissemination exists for all patients with newly diagnosed epend-
ymoma, disease staging, including both craniospinal MRI and CSF cytology, is manda-
tory following surgery (not earlier than 2–3 wk).
n.a. Good Practice Point
Postoperative conformal radiotherapy with doses up to 60 Gy is recommended for 
patients with WHO grade III (anaplastic) ependymomas regardless of the extent of 
resection.
II B
Postoperative conformal radiotherapy with doses of 54–59.4 Gy is recommended for 
patients with WHO grade II ependymomas following incomplete resection.
III C
Craniospinal irradiation (CSI) of 36 Gy is recommended in case of CSF or spinal dissem-
ination with a boost up to 45–54 Gy on focal lesions.
IV Good Practice Point
Because of the risk of asymptomatic and/or late relapses, patients should be followed 
long term with contrast-enhanced MRI.
n.a. Good Practice Point
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Clinical and Neuroimaging Diagnosis
The clinical presentation of ependymomas (see 
Supplementary material) depends primarily on patient 
age, tumor location, and tumor size.10–14
MRI with contrast enhancement is the modality of choice 
for diagnosing ependymal tumors.15,16 CT can better 
depict calcifications, which are most commonly observed 
in subependymomas. Infratentorial ependymomas arise 
from the floor of the fourth ventricle, while supratento-
rial ependymomas can be located in the brain rather than 
in the ventricles. Intracranial ependymomas commonly 
appear as well-circumscribed mass lesions and have a het-
erogeneous appearance on T1-, T2-, and postcontrast MRI, 
displaying varying degrees of contrast enhancement.
Advanced imaging modalities may assist in diagnosis or 
management in some clinical scenarios; however, the avail-
able data from the literature are too scarce and do not allow 
for definitive recommendations for daily clinical practice. 
Diffusion-weighted imaging may be useful for differentiat-
ing pilocytic astrocytomas, medulloblastomas, and epend-
ymomas in the posterior fossa.17 MR spectroscopy reveals 
elevated choline and reduced N-acetylaspartate levels.8 
Perfusion MRI may display elevated cerebral blood volume 
values and have some prognostic value.18 Spinal cord epend-
ymomas display more distinct borders than diffuse astrocy-
tomas.14 Cyst formation and T2 hypointensity of the cyst wall 
due to blood products (“hemosiderin cap”) are suggestive of 
ependymoma. An associated syringomyelia is common.
Myxopapillary ependymoma (MPE) is typically located 
in the conus medullaris, cauda equina, and filum terminale 
region.
Neuropathological Diagnostics of 
Ependymal Tumors
Ependymal tumors are classified according to the WHO 
classification of CNS tumors 2016.3 Histological assess-
ment is primarily based on hematoxylin/eosin-stained 
sections and some ancillary techniques, including silver 
impregnation for reticulin fibers, Alcian blue for demon-
stration of mucoid changes, and periodic acid–Schiff stain-
ing for glycogen. Immunohistochemically, ependymal 
tumors react positive for glial fibrillary acidic protein and 
protein S100 but usually lack nuclear positivity for OLIG2. 
Dot-like perinuclear and ring-like cytoplasmic immunore-
activity for epithelial membrane antigen is a characteristic 
feature.19 Nuclear immunoreactivity for v-rel avian reticu-
loendotheliosis viral oncogene homolog A  (RELA) and 
expression of L1 cell adhesion molecule may help to iden-
tify RELA fusion-positive ependymomas.20,21 However, 
molecular testing for C11orf95-RELA fusion by fluorescent 
in situ hybridization or reverse-transcription PCR analysis 
is required for a firm diagnosis.3 Loss of nuclear expres-
sion of trimethylated histone 3 lysine 27 (H3-K27me3) 
distinguishes a prognostically unfavorable group of pos-
terior fossa ependymomas (PF-EPNs) in children,22 largely 
corresponding to PF-EPN group A  (see “New Molecular 
Subgroups” section below).6,23 Proliferative activity is 
commonly assessed by Ki-67 immunostaining; however, 
definite cutoffs for grading have not been defined.
The 2016 WHO classification of CNS tumors includes 
5 distinct entities of ependymal tumors.3 Myxopapillary 
ependymoma WHO grade I  is histologically character-
ized by cuboidal or elongated tumor cells forming fibrillary 
Table 2 Key recommendations for the treatment of newly diagnosed intracranial WHO grades II and III ependymomas in children
Class of 
Evidence
Level of Recommendation
Resection is recommended to obtain a histological diagnosis and should be a gross total 
resection whenever feasible. As the morbidity can be significant, detailed informed pre-
operative counseling by a surgeon experienced in performing such surgery is important.
II B
Postoperative MRI should be performed to evaluate the extent of resection. n.a. Good Practice Point
A second-look surgery should be considered when residual tumor is demonstrated on 
postoperative MRI and gross total resection is a realistic goal.
II B
Because a risk of CSF dissemination exists for all patients with newly diagnosed epend-
ymoma, a disease staging, including both craniospinal MRI and CSF cytology, is manda-
tory following surgery (not earlier than 2–3 wk)
n.a. Good Practice Point
Postoperative conformal radiotherapy with doses up to 59.4 Gy is recommended in chil-
dren older than 18 months.
II B
Postoperative conformal radiotherapy with doses of 54 Gy is recommended in children 
between 12 months and 18 months or in older children with poor neurological status.
II B
Chemotherapy alone is an option in children less than 18 months old, while it is recom-
mended in children aged less than 12 months.
III C
Craniospinal irradiation (CSI) is recommended in case of CSF or spinal dissemination 
with a boost on focal lesions with doses adapted to patient age.
IV Good Practice Point
Because of the risk of asymptomatic and/or late relapses, patients should be followed 
long term with an enhanced MRI.
n.a. Good Practice Point
Serial monitoring of cognitive and endocrine functions with specific batteries following 
radiotherapy is recommended whenever feasible.
n.a. Good Practice Point
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processes toward fibrovascular cores typically showing 
perivascular mucoid degeneration. Mitotic activity is low. 
Subependymoma WHO grade I is characterized by clusters of 
bland to mildly pleomorphic, mitotically inactive cells embed-
ded in an abundant fibrillary matrix with frequent microcystic 
changes and dystrophic calcifications. Ependymoma WHO 
grade II usually shows a solid, well-circumscribed growth 
and is composed of uniform cells forming perivascular pseu-
dorosettes and, in some tumors, true ependymal rosettes. 
Mitotic activity is low while non-palisading necroses may 
be present in a fraction of cases. Three variants of epend-
ymoma, each characterized by distinct histological features, 
are recognized in the WHO classification, namely papillary 
ependymoma, clear cell ependymoma, and tanycytic epend-
ymoma. Ependymoma, RELA fusion-positive is a novel 
supratentorial ependymoma entity that is defined by the 
presence of a C11orf95-RELA fusion.6,20 It may correspond 
to WHO grade II or III, but patient outcome is worse com-
pared with other types of supratentorial ependymomas.6 
Anaplastic ependymoma WHO grade III carries histological 
features of anaplasia, in particular high mitotic activity and 
microvascular proliferation. Pseudopalisading necrosis may 
also be observed. However, accurate histological distinction 
of WHO grades II and III ependymomas is challenging and 
its role in predicting survival has been disputed.24 Hence, 
WHO grading is inadequate to reliably predict the outcome 
in individual patients, and molecular subgrouping or single 
molecular markers may offer new perspectives for improved 
prognostic stratification.4,6,25–27
Treatment of Newly Diagnosed 
Intracranial Ependymal Tumors 
in Adults
Adult intracranial ependymomas are rare tumors, and 
WHO grade II tumors are more frequent than WHO grade III 
(anaplastic) counterparts.10
Surgery is considered the first and crucial step of stand-
ard treatment. In the majority of studies, extent of resec-
tion has emerged as one of the most significant predictors 
of outcome.28–33 In a retrospective series of WHO grade 
II ependymomas in adults,31 the 5- and 10-year OS rates 
were 86.1% and 81%, respectively. Preoperative KPS, 
extent of resection, and tumor location were independent 
prognostic factors for OS. In particular, gross total resec-
tion (GTR), defined as no residual disease on postcontrast 
T1- and T2-weighted images on a 3-month postoperative 
MRI, and infratentorial location were associated with a 
longer OS. GTR and tumor location were also independ-
ent factors predicting progression-free survival (PFS). 
Conversely, incomplete resection has an increased risk 
of tumor recurrence and CSF dissemination. However, in 
posterior fossa tumors, encasement of the cranial nerves 
and brainstem vasculature might limit resectability.34 In 
case of persistent hydrocephalus despite tumor resec-
tion, shunting or endoscopic ventriculostomy needs to be 
performed.
Concepts regarding target volume for radiation ther-
apy have evolved. In the past, patients with ependymoma 
often received craniospinal irradiation. However, numer-
ous studies demonstrated the efficacy of local fields in the 
treatment of ependymoma, achieving good local control 
with low risk of spinal dissemination.35 In adults, there 
is agreement that postoperative radiotherapy should be 
included in the standard of care for patients with ana-
plastic ependymoma (WHO grade III) and for patients 
with ependymomas (WHO grade II) after an incomplete 
resection.29,36 Conversely, the role of postoperative radio-
therapy in patients with ependymoma WHO grade II 
undergoing GTR remains controversial.37 In 2 large retro-
spective studies including patients with intracranial WHO 
grade II ependymomas,31,38 no significant association 
of radiotherapy with PFS or OS was found. However, in 
the French study,31 the subgroup of patients with incom-
pletely resected tumors receiving postoperative radio-
therapy had longer PFS and OS than those who did not.
Intracranial subependymoma is a rare WHO grade 
I  tumor. Long-term survival can be expected after sur-
gical removal, although poorly defined borders have 
been reported to be associated with a shorter PFS.39 
Postoperative radiotherapy has been employed in few 
patients after subtotal or partial resection.
Recommendations regarding treatment of intracranial 
ependymomas in adults are summarized in Table 1.
Table 3 Key recommendations for the treatment of recurrent intracranial ependymomas in adults and children
Class of 
Evidence
Level of Recommendation
Re-operation and/or re-irradiation should be proposed whenever possible. However, if 
only incomplete resection was achievable due to functional restrictions at first surgery, 
the same limitations will be faced at re-operation; hence, in these cases the indication for 
another incomplete resection should be made cautiously.
III C
In patients with recurrent ependymomas who are no longer eligible for local treatments, 
chemotherapy might be warranted, particularly in patients with a good performance 
status.
III C
In adults, either platinum compounds or temozolomide (based on a more favorable tox-
icity profile) should be considered. Options for participation in a clinical trial should be 
explored.
IV Good Practice Point
In children, the choice of chemotherapeutic drugs depends on previous exposures. 
Options for participation in a clinical trial should be explored.
n.a. Good Practice Point
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Treatment of Newly Diagnosed 
Intracranial Ependymal Tumors in 
Children
More than half of all pediatric ependymomas occur in 
children younger than 3 years,40 and about two thirds of 
tumors are located in the posterior fossa.32
Surgery and radiotherapy are the mainstay of treatment 
for ependymomas in children.41 Extent of resection is the 
most important prognostic factor, but the site of the lesions 
(eg, posterior fossa tumors involving the ponto-cerebellar 
region) can limit surgery due to involvement of the lower 
cranial nerves and brainstem42; thus, an incomplete resec-
tion is frequent in these patients. OS is around 70% at 
5 years in case of GTR, but it is much lower with incomplete 
resection.43–45 A second-look surgery is increasingly under-
taken when the first resection has been incomplete.46–48
The benefit of postoperative radiotherapy has been 
shown in terms of local control and survival rates in chil-
dren with intracranial ependymomas.45 An Italian study44 
reported on attempted GTR followed by postoperative 
radiotherapy and showed a 7-year estimate of local con-
trol, event-free survival (EFS), and OS of 83.7%, 69%, and 
81%, respectively. Data from St Jude Children’s Research 
Hospital45 showed improved local control, EFS, and OS 
with 59.4 Gy in 1.8 Gy fractions with 3D conformal radio-
therapy without any apparent increase of late neurocog-
nitive deficits. Therefore, postoperative radiotherapy with 
59.4 Gy (1.8 Gy/fraction) has been advocated45 for children 
older than 3 years, while for children as young as 18 months 
or children with altered neurological status, the doses can 
be lowered to 54 Gy.49 This can be true even for children 
between 12 and 18 months. A recent retrospective study on 
206 patients reported that the main pattern of relapse was 
within the radiation fields even at 59.4 Gy.50 As local control 
remains the primary goal of treatment, the possibility to 
compensate for an incomplete surgery by applying a hypo-
fractionated stereotactic boost in addition to conventional 
radiotherapy has been proposed.51 In an Italian prospect-
ive clinical trial, patients with residual disease after first 
surgery who received a boost of 8 Gy in addition to radi-
ation and chemotherapy had a 5-year PFS rate higher than 
58%.52 A prospective study has shown that hyperfraction-
ated radiotherapy is safe but provides no outcome benefit 
compared with standard fractionated regimens.53
The toxicity of radiotherapy in younger children is of 
concern, and intensity-modulated radiation therapy has 
been employed to limit late sequelae.44 Merchant and col-
leagues54 developed a model combining dose-volume data 
with clinical factors to predict intelligence quotient (IQ) 
outcomes and concluded that the radiation dose remains 
the most clinically significant determinant of IQ outcomes 
and that even low doses, such as <20 Gy, delivered to the 
supratentorial brain, have an impact on the IQ. Proton 
therapy could be an alternative to conventional photon 
radiotherapy.55 In this regard, the Massachusetts General 
Hospital group reported the outcome of 70 children with 
localized ependymomas treated with proton therapy.56 At a 
median follow-up of 46 months, local control and survival 
were excellent and the complication rate particularly low. 
Proton therapy may be useful for PF-EPN,57 as it can spare 
the dose exposure to supratentorial compartments of the 
brain and auditory structures. Supratentorial ependymo-
mas, which are often large tumors and occur in children 
over 10 years of age, also could represent a good indica-
tion for proton therapy in order to reduce neurocognitive 
impairment, and in this regard the preliminary data are 
encouraging.58
However, recent studies59–61 have suggested that brain-
stem toxicity, including radiation necrosis, with proton 
treatment can occur. Thus, it has been recommended to 
limit the dose to the brainstem. Another study reported 
more imaging changes in brainstem with protons than with 
photons.62 The benefit and risks of proton therapy need to 
be confirmed with modern proton treatments and in pro-
spective studies.63 A  prospective study (NCT01288235) 
with proton therapy is ongoing in the US.
The role of chemotherapy in children remains unproven 
despite intensive investigation.64 As there is reluctance 
to deliver radiation to very young children, postopera-
tive chemotherapy has been frequently proposed, while 
in older children chemotherapy is delivered as an adjunct 
to radiotherapy. Postoperative chemotherapy, using vari-
ous combinations of etoposide, vincristine, cyclophospha-
mide, platinum derivatives, and high-dose methotrexate, 
showed a 40% to 50% response rate.44,65–67 The role of 
intensified schedules of chemotherapy was suggested in 
baby protocols,66 especially for supratentorial tumors.68 
In contrast, the use of immediate postoperative high-
dose conformal radiotherapy in children under the age of 
3 years led to 7-year PFS rates of 77%,45 albeit long-term 
follow-up for toxicity on development is pending. Thus 
far, radiotherapy deferral strategies that use chemother-
apy have been abandoned in most institutions for children 
aged more than 12 months.
Two randomized trials are currently comparing post-irra-
diation chemotherapy with observation.
Recommendations regarding treatment of intracranial 
ependymomas in children are summarized in Tables 2, 3, 
and 4. A summary of prospective studies on radiotherapy 
in pediatric patients with ependymoma can be found in the 
Supplementary material.
Treatment of Recurrent Intracranial 
Ependymal Tumors in Adults and 
Children
Standard salvage options for recurrent ependymomas 
have not been identified. However, re-operation as well as 
re-irradiation are increasingly employed.
Re-operation has been shown to be associated with 
improved prognosis.69 Among children who underwent re-
operation, there was a 5-year EFS of 19% in case of GTR, 
of 14% in case of incomplete resection, and of 8% without 
repeat surgery.70 Re-irradiation is performed in adults as well 
as in children, using either a full course of fractionated irradi-
ation69,71 or hypofractionated stereotactic irradiation72–76 or 
proton therapy,77 and can achieve durable responses.
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The role of chemotherapy for treatment of recurrent 
ependymoma in adults remains unclear and is considered 
only when local treatment options (surgery and radiother-
apy) have been exhausted.78,79
Similar to other gliomas, temozolomide (TMZ) has been 
used for the treatment of adult patients with ependymoma. 
Some case reports suggested that TMZ alone or in combin-
ation is active against recurrent WHO grade II or III epend-
ymoma.80–84 A  retrospective study of 18 patients with 
recurrent WHO grades II and III intracranial ependymomas 
failing re-operation or re-irradiation or both suggested 
an activity of TMZ in the standard schedule both in terms 
of response (22% complete  +  partial) and outcome (PFS 
9.69 mo and OS 30.55 mo).85 Responses were observed 
in chemotherapy-naïve patients only and in most cases 
were delayed in appearance. Conversely, in another retro-
spective study86 of patients with WHO grade II intracranial 
ependymomas refractory to first-line chemotherapy with 
platinum compounds, TMZ in the standard schedule had 
a more limited activity with a response rate of 4%, a PFS 
of 2 months, and OS of 3 months. An explanation of this 
difference could be that all patients of this cohort86 were 
heavily pretreated, while the majority of patients of the 
other cohort85 were chemo naïve, thus receiving TMZ in an 
earlier phase of the disease. Temozolomide has also been 
used in combination with lapatinib in a single-arm phase 
II study in patients with recurrent intracranial and spinal 
ependymoma.87 Lapatinib targets the epidermal growth 
factor receptor (ErbB1) and the related family member 
human epidermal growth factor receptor 2/neu (ErbB2), 
which are expressed on the surface of ependymoma cells. 
Fifty patients were enrolled in this trial and the treatment 
was overall well tolerated. Median PFS was 45 weeks for 
patients with WHO grade II, and 25.3 weeks for patients 
with WHO grade III anaplastic ependymomas. Responses 
to treatment correlated with higher ErbB2 mRNA expres-
sion in the tumor tissue. The rather modest activity of 
TMZ against ependymoma might be due to the lack of O6-
methylguanine-DNA-methyltransferase (MGMT) promoter 
methylation in ependymoma cells88,89; however, even 
when present, MGMT promoter methylation may not cor-
relate with response to TMZ.85
A few studies on the administration of platinum-based 
regimens, using either cisplatin or carboplatin, have been 
published. A retrospective study, including pediatric as well 
as adult patients, indicated a superiority of platinum-based 
over nitrosourea-based regimens.90 Another retrospect-
ive series reported higher response rates in patients with 
progressive or recurrent ependymoma treated with cis-
platin compared with nonplatinum regimens, but no differ-
ence in terms of PFS and OS was observed.91 Other drugs 
and regimens, such as tamoxifen and isotretinoin, were 
used in only single patients.92 The anti-angiogenic agent 
bevacizumab has been administered in a small cohort of 8 
patients with recurrent WHO grade II or III adult intracranial 
ependymoma with a median PFS of 6.4 months and OS of 
9.4 months.93
Phase II studies in children with relapsing ependymo-
mas have reported a low response rate with either stand-
ard94 or high-dose chemotherapy.95 Metronomic therapies 
have produced some long-term stabilizations.96 Responses 
have been reported with oral etoposide97 or TMZ.98 
Bevacizumab, in association with either irinotecan99 or 
lapatinib,100 has proven disappointing. Targeted agents, 
such as erlotinib97 and sunitinib,101 failed to show activity 
in unselected patient cohorts.
Recommendations regarding treatment of recurrent 
ependymomas are summarized in Table 3.
Treatment of Ependymal Tumors of the 
Spinal Cord
Ependymal tumors of the spinal cord are more common 
in adults than in children.10 They include WHO grade I   
subependymoma and MPE, and WHO grades II and III (ana-
plastic) ependymoma. Spinal cord ependymomas have a 
better prognosis than spinal cord astrocytomas, but fac-
tors affecting prognosis have not been defined except 
for GTR.102 Advances in microsurgical techniques have 
allowed en bloc GTR over piecemeal subtotal resection 
(STR) as standard of care for spinal cord ependymomas. 
In the majority of cases a GTR can be performed with good 
functional results. Since good functional outcome is related 
to small tumor size and good neurological status at the 
time of surgery, resection is considered at an early stage 
of the disease.103,104 When GTR is not feasible because of 
infiltration of spinal cord or nerve roots, postoperative 
local radiotherapy is commonly employed. A recent review 
of the literature has been performed for 348 patients with 
WHO grades II and III spinal cord ependymomas who 
underwent surgery with known extent of resection (GTR 
or STR), with or without postoperative radiotherapy.105 
After multivariate analysis, extent of resection and tumor 
grade were independent prognostic factors for OS and 
PFS, and radiotherapy prolonged PFS in patients receiving 
STR: median PFS was 48 months in patients treated with 
STR alone and 96 months for patients treated with STR fol-
lowed by radiotherapy. The optimal dose is still a matter of 
debate, with studies suggesting either better or equivalent 
results with doses >50 Gy.105,106
Regarding conventional chemotherapy, a small study of 
10 patients with recurrent intramedullary ependymoma 
has reported that continuous oral etoposide is well toler-
ated and may be active.107 Bevacizumab can provide clin-
ical benefit in some patients, although the changes on 
MRI do not meet the current criteria for radiological tumor 
response.108
Recommendations regarding treatment of spinal cord 
ependymomas are summarized in Table 5.
Large retrospective series on MPE have been performed, 
including a large multi-institutional series of 183 patients109 
that showed a 10-year OS of 92.4% and a 5- and 10-year 
PFS of 69.5% and 61.2%. MPE recurrence was local in 84% 
of patients, and leptomeningeal spread was observed in 
9.3% of patients. Extent of resection was a major inde-
pendent factor predicting local control, while younger age 
(<36 y) was a negative prognostic factor. However, the 
irregular shape, contact with surrounding nerve roots, and 
production of a myxoid matrix, particularly in the filum ter-
minale, can make GTR particularly challenging with risks 
Downloaded from https://academic.oup.com/neuro-oncology/advance-article-abstract/doi/10.1093/neuonc/nox166/4673200
by University of Torino user
on 11 January 2018
 8 Rudà et al. EANO guidelines on ependymomas
of postoperative neurological disability. A  strong correl-
ation between capsular violation at surgery and recurrence 
has been found.110 An OS at 10 years exceeding 90% has 
been recently confirmed in an analysis by the Surveillance, 
Epidemiology, and End Results (SEER) program of 773 
patients.111 Presacral MPE shows a worse outcome com-
pared with MPE of the filum terminale/cauda equina 
region.
Compared with patients treated with surgery alone, post-
operative radiotherapy, especially with high doses (≥50 
Gy), has been shown to increase the local control and PFS 
(10-y PFS from ˂40% to 70%) with good tolerance and with-
out substantial late toxicity.112,113 A  small series on adult 
patients with spinal MPE has shown that patients treated 
by GTR followed by adjuvant radiotherapy had better local 
control than patients treated with GTR alone.114 However, 
prospective confirmatory data are needed.
MPE is very rare in children. Although patients frequently 
present with disseminated tumor and/or develop recurrent 
or progressive disease following treatments,115 the OS at 5 
and 10 years in the SEER database is estimated at 97% and 
95%, respectively.116 A  recent series from Johns Hopkins 
Hospital117 indicated a significant reduction in local failure 
for patients receiving radiotherapy following STR or GTR. 
A smaller series118 also confirmed good local control with 
surgery and radiotherapy compared with GTR alone.
Recommendations on treatment of MPEs are summa-
rized in Table 6.
New Molecular Subgroups: Implications 
for Management
The aforementioned international molecular classification 
recognizes 9 molecular subgroups of ependymal tumors, 3 
in each anatomical compartment of CNS: spine (SP), pos-
terior fossa (PF), and supratentorial region (ST).6 One of 
the subgroups within each compartment corresponds to 
WHO grade I  subependymomas (SEs: SP-SE, PF-SE, and 
Table 6 Key recommendations for the treatment of MPEs WHO grade I
Class of  
Evidence
Level of Recommendation
Gross total resection is recommended whenever feasible. II B
Postoperative MRI should be performed to evaluate the extent of resection. n.a. Good Practice Point
Because a risk of CSF dissemination exists for all newly diagnosed patients, disease 
staging, including both craniospinal MRI and CSF cytology, is recommended following 
surgery (not earlier than 2–3 wk).
n.a. Good Practice Point
Postoperative radiotherapy with doses ≥50 Gy is recommended in case of incomplete 
resection.
II B
In case of relapse, consideration should be given to re-operation, re-irradiation, and 
chemotherapy.
III C
Because of the risk of asymptomatic and/or late relapses, patients should be followed 
long term with an enhanced MRI.
n.a. Good Practice Point
Table 5 Key recommendations for the treatment of WHO grades II and III spinal cord ependymomas
Class of 
Evidence
Level of Recommendation
Gross total resection is the goal of spinal ependymoma surgery. II B
Postoperative MRI should be performed to evaluate the extent of resection. n.a. Good Practice Point
Because a risk of CSF dissemination exists for all patients with newly diagnosed epend-
ymoma, disease staging, including both craniospinal MRI and CSF cytology, is recom-
mended following surgery (not earlier than 2–3 wk).
n.a. Good Practice Point
In case of WHO grade III (anaplastic) ependymomas, postoperative radiotherapy with 
doses of 45–54 Gy is recommended regardless of the extent of resection.
III C
In case of WHO grade II ependymomas following gross total resection, a watch-and-wait 
strategy is recommended.
III C
In case of incomplete resection of a WHO grade II ependymoma, postoperative local 
radiotherapy is recommended with doses of 45–54 Gy.
II B
Because of the risk of asymptomatic and/or late relapses, patients should be followed 
long term with an enhanced MRI.
n.a. Good Practice Point
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ST-SE), occurs exclusively in adults, and shows favorable 
prognosis, while the 2 other molecular subgroups within 
the spine predominantly correspond to the histological 
diagnoses of MPE (SP-MPE) and WHO grades II–III epend-
ymoma (SP-EPN).6
Two molecular types of ependymomas have been identi-
fied in the posterior fossa, termed PF-EPN-A and PF-EPN-B 
(group A and group B). PF-EPN-A tumors occur predom-
inantly in infants and young children, are often in a lateral 
location and difficult to resect completely, and are associ-
ated with a high recurrence rate.23 Conversely, PF-EPN-B 
tumors occur largely in adolescents and young adults and 
are associated with a more favorable prognosis. Data from 
a recent retrospective study on 4 independent nonoverlap-
ping cohorts of PF-EPNs119 found that patients with either 
group A or group B tumors appeared to benefit from GTR, 
with the survival rates being particularly poor for subtotally 
resected PF-EPN-A, even in association with radiation ther-
apy. Moreover, a large subset of patients with PF-EPN-B 
who received a GTR did not recur even without adjuvant 
radiotherapy. Based on these data, participants in a multi-
disciplinary international consensus conference120 agreed 
that for PF-EPN-A tumors in patients older than 12 months, 
maximal safe resection and focal radiotherapy should be 
defined as standard of care; furthermore, due to the chal-
lenging localization of tumors, patients would benefit from 
being treated in specialized centers by experienced neuro-
surgeons. Conversely, for patients with PF-EPN-B tumors 
undergoing GTR, a randomized clinical trial comparing 
observation versus standard focal radiotherapy could be 
launched.
A number of ST-EPNs are characterized by fusions 
between C11orf95 and the RELA gene (ST-EPN-RELA)6,20 
and occur in both children and adults. Retrospective stud-
ies have suggested that these tumors are associated 
with a poor prognosis, extent of resection not being sig-
nificantly associated with outcome. Thus, in this patient 
population, postoperative radiotherapy seems to be rec-
ommended. Another molecular subgroup of ST-EPNs har-
bors recurrent fusion with the oncogene YAP1, is enriched 
in the pediatric population, and shows a favorable prog-
nosis.6,20 Gain of chromosome arm 1q occurs in a subset 
of PF-EPN-A, PF-EPN-B, and ST-EPN-RELA tumors and has 
been shown to be an independent negative prognostic 
factor.26,121,122
In conclusion, all these molecular subtypes with distinct 
prognosis will hopefully benefit from distinct personalized 
therapies. Table 4
Supplementary Material
Supplementary material is available at Neuro-Oncology 
online.
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